EXEL vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 13, 2026
EXEL
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | EXEL | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 13.6054 | 23.0415 | EXEL |
| PEG Ratio | 2.2685 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 10.6% | 2.1% | EXEL |
| Earnings Growth | 26.2% | -85.1% | EXEL |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 41.2/100 | 39.1/100 | EXEL |
| Profit Margin | 35.3% | -141.4% | EXEL |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | SELL | EXEL |
Relative Price Performance (Last 90 Days)
Current Technical Phase
EXEL
MarkupPrice above SMA50, rising 50-day trend (2.1% over 20 days), RSI 51
MRNA
MarkupPrice above SMA50, rising 50-day trend (50.4% over 20 days), RSI 61
Fundamentals Snapshot
| Metric | EXEL | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 13.2 | -29.2 |
| Trailing P/E | 18.3 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 1.0% | -0.7% |
| Operating Margin | 0.4% | -5.6% |
| EPS | 3.13 | -8.03 |
| Dividend Yield | — | — |